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 Abstract .  
Evidence in inflammatory bowel diseases (IBD) 
supports a connection between inflammation and cancer 
due to the alteration of the cell cycle with loss of control 
at the G1/S checkpoint. In this study, we analyze the 
expression and modulation of CyD1 and E2F1 in colon 
explants from Crohn's disease (CD) patients.  
We used ex vivo culture of colon explants from 4 CD 
patients and 2 healthy controls, stimulated with 
lipopolysaccharide from Escherichia Coli (EC-LPS). 
Commercial siRNAs for CyD1 and E2F1 inhibition were 
encapsulated in Invivofectamine® and in purposely 
produced nanoliposomal vectors to silencing CyD1 and 
E2F1 expression. Western blot analysis was used to 
investigate the effect of siRNA on CyD1, E2F1 and 
cyclooxygenase 2 (COX-2) expression. In CD patients 
colon explants, CyD1 and E2F1 increased after the 
inflammatory stimulus but siRNA silencing attenuated 
their expression and controlled the COX-2 expression too. 
These data represent a prelimiary exploration of in vitro 
siRNA use. 
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 The etiopathogenesis of Crohn's disease (CD) 
and ulcerative colitis (UC), the major forms of 
inflammatory bowel diseases (IBD), is still unknown.  
Many evidence indicates that the IBD-associated tissue 
damage is due to an exaggerated mucosal inflammatory 
response [1, 2]. IBD patients show systemic inflammation 
and some related morbidities [3-7].  mong morbidities, 
younger patients with CD have also an increased risk of 
ischemic stroke [8]. Moreover, there is evidence that the 
chronic inflammation is pro-carcinogenic [9]. In fact, 
people affected by chronic intestinal inflammation, either 
with colonic CD or UC, have as well as in other chronic 
inflammatory conditions, an increased colonic cancer risk 
[10-12]. However, little is known about the key steps 
regulating the carcinogenetic process in IBD. Genetic 
mutations, microsatellite instability, and DNA 
hypermethylation promote uncontrolled proliferation that 
leads to crypt elongation and, eventually, adenoma 
formation and tumor progression [13, 14].  Many studies 
suggest a relationship between inflammation, cell cycle 
progression and cancer.   
In the relation between cancer and inflammation, NF-
κB plays an important role by orchestrating inflammatory 
responses, cell survival and growth [11]. Experimental 
data evidence the involvement of NF-κB in colorectal 
carcinogenesis. NF-κB potentiates tumor proliferation and 
growth by upregulating the phosphoinositide 3-kinase 
(PI3K)/Akt cascade and crucial cell-cycle (cyclin-D1, 
cmyc) and anti-apoptotic pathways (Bcl-XL, inhibitor of 
apoptosis proteins (IAPs). Additionally, by mediating the 
production of cyclooxygenase-2 (COX2), vascular 
endothelial growth factor (VEGF), interleukin (IL)8, 
intracellular cell adhesion molecule (ICAM), vascular cell 
adhesion molecule (VCAM) and matrix 
metalloproteinases (MMPs) it enhances angiogenesis and 
invasiveness  [15].   In the cancer progression CDK4 
kinase controls cell cycle transition from G1 to S phase 
[16].  The alteration in CDK4 function is demonstrated in 
colorectal cancer [17], breast cancer [18, 19], ovarian 
cancer [20, 21], lung cancer [22, 23], pancreatic cancer 
[24], and prostate cancer [25]. CDK4 knockout 
completely eliminates multiple endocrine neoplasia type 
1- induced pituitary and pancreatic islet carcinogenesis 
[26, 27]. Among the players regulating inflammation and 
cell cycle, E2F1 and CyD1 are genes regulating the 
cyclin-dependent kinase (cdk) –retinoblastoma (–Rb) 
pathway [28]. Recent studies indicate that the molecular 
mechanisms employed by nuclear cdks support the 
expression of inflammatory mediators; some 
proinflammatory genes are overexpressed during the G1 
phase of the cell cycle, and depend on cdks [29]. For 
example, the cytokine-induced recruitment of CDK6 to 
the nuclear chromatin fraction is associated with 
transcription factors of the NF-κB, STAT, and AP-1 
families [16]. 
CyD1 is a proto oncogene and a primary regulator of cell 
proliferation, acting as a mitogen sensor that correlates 
cellular signaling mechanisms to the cell cycle. [30] 
Previous studies suggest that pRb, p16 and CyD1 are 
abnormally expressed in both colorectal adenomas and 
adenocarcinomas demonstrating a correlation between 
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these factors. [31]. In inflammatory bowel diseases, colon-
expressed CyD1 is aberrantly upregulated in both 
epithelial and immune cells [32]. Moreover, previous 
studies suggest that also E2F1 release has a role in the 
inflammatory response in patients with colitis, by the 
activation of P53 [33]. Also E2F1 is a key player in the 
inflammation control due to its relation to retinoblastoma 
protein (pRb). pRb controls cell cycle entry through the 
induction of transcription factors of the E2F family. After 
growth signals, pRb is hyper-phosphorylated by cdk 
complexes such as cyclin D/cdk4/6 and cyclin E/cdk2. 
[34] Overexpression of CyD1 is an early event in 
intestinal progression to cancer [35, 36] and dynamic 
expression of this cyclin is crucial for intestinal cell 
proliferation and maintenance of the transformed 
phenotype in mouse models and human colon cancer cells 
[37, 38]. However, in CyD1 knockout mice, intestinal 
tumors still developed, although in a reduced number [25]. 
This datum supports the hypothesis that CyD1 may not be 
essential for intestinal tumorigenesis, but it may act as a 
modifier gene [39] and it can be induced by NF-B. This 
hyper-phosphorylation causes E2F release and 
transcription of other growth-associated genes.  E2F1 
seems to be a promising regulator in ovarian carcinoma 
and early studies suggest that E2F1 was significantly 
overexpressed in hepatocellular carcinoma and played a 
causative relationship with cell proliferation [40]. Also the 
cyclooxygenase 2 (COX2), a protein involved in 
inflammation, is increased in more aggressive forms of 
colorectal cancer, and is known to promote angiogenesis. 
[41] Accumulating evidence has  also, demonstrated that 
cyclooxygenase-2 (COX-2) is involved in head and neck 
cancers, especially in nasopharyngeal carcinoma (NPC). 
[42]. COX-2 is a key isoenzyme in this biochemical 
cascade and is inducible by various oncogenic stimuli. A 
large volume of research data has shown that COX-2 is 
often upregulated in many malignant tumours, rendering it 
an attractive candidate target for cancer therapeutics [43].  
One way to control the cell cycle are the siRNAs, 
powerful 20-25 bp double-stranded nucleotides, which can 
post-transcriptionally silence the gene expression 
modifying the related proteins expression levels [44]. 
siRNAs have a potential as drugs in the treatment of 
inflammation and cancer diseases but due to their 
hydrophilic nature and being negative charged they cannot 
cross cellular membrane and reach the nucleus [45]. 
Moreover, siRNAs are rapidly degraded by nucleases and 
cannot maintain their integrity for a long time [46]. Hence, 
there is a need for siRNA carrier systems to minimize 
siRNAs degradation and loss and, at the same time, 
increase their absorbance and bioavailability, favoring 
their biodistribution and penetration in the cellular 
compartment. Nanoliposomes-based drug delivery is an 
innovative and promising system to transport and control 
siRNAs release and overcome some of their limitations. 
[47-49] 
In this regard, one of the main liposomes feature is their 
flexibility to link with site-specific ligands, molecules 
which allow achieving an active targeting, achieving the 
siRNA release only in the diseased tissue, without 
affecting the surrounding healthy tissue. Safety and 
efficacy are granted by smart-liposomes with tailored 
features regarding size, charge, load capability, and the 
ability to respond to stimuli. In fact, tailored carriers will 
take into account not only the drug features but also those 
of the tissue to be treated [50,51]. The intestinal 
epithelium is ideal for studying the mucosal homeostasis 
and cancer induction, because it is a rapidly proliferating 
tissue, and the mucosal homeostasis is dependent on the 
precise control of cellular proliferation within intestinal 
crypts. In particular, gut organ tissue explants are a 
suitable model to study the mechanisms that regulate the 
cell cycle progression and their potential control [52]. 
The aim of this study is to analyze the expression of CyD1 
and E2F1 in colon tissues specimens from patients 
affected with Crohn’s disease after culture, and the 
efficacy of purposely formulated and produced siRNA 





 Tissue Culture 
Blind to the characteristics of the patients, the in vitro 
organ cultures were performed by collecting intestinal 
specimen biopsy fragments from a healthy control and 
patients affected with Crohn’s disease during lower 
endoscopy. Healthy controls underwent colonoscopies 
because of colonic cancer screening, while Crohn’s 
disease patient underwent endoscopy as per routine 
follow-up.  Exclusion criteria were age < 18 yrs, lack of 
informed consent, past or current therapy with 
immunosuppressant and/or biological agents, current 
therapy with steroids.  A minimum of 14 fragments was 
needed for each experiment. The fragments were taken in 
the colon from uninflammed areas but next to the affected 
mucosa.  Two fragments were oriented on Whatman paper 
and used for routine histology. The remaining 12 
fragments were used for the experiment and placed in an 
ice-cold tissue-culture medium within 20 minutes and 
cultured as follows. To obtain the best results fragments 
are placed on a stainless-steel mesh in the well of an 
organ-culture dish containing culture medium with the 
epithelium facing upward. The dish is placed in a modular 
incubator chamber, supplemented with RPMI 1640 and 
10% of fetal bovine serum, gassed with 5% CO2 and 95% 
O2, and then incubated at 37°C for a different time. [53] 
In this study we treated the colon biopsies with the siCy 
D1 and siE2F1 in presence or absence of EC-LPS 
(Lipopolysaccharides from Escherichia Coli, Sigma-
Aldrich Co, MI; 2 µg/ml) and, after 24 h of incubation, we 
analyzed the tissue integrity and the CyD1 and E2F1 
expression through Western Blotting technique. We also 
treated the colon biopsies with nanoliposomes conjugated 
with Rhodamine, incubating them for 4h. The study was 
approved from Campania Sud Ethical Committee.  
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Immunohistochemical analysis 
After ex vivo colon explant culture, serial 5 µm sections 
were stained with Hematoxylin and Eosin (H&E) and 
Masson's Trichrome.  Immunohistochemical (IHC) 
analysis if sections was perfomed incubating them for 40 
minutes in methanol and 3% hydrogen peroxidase solution 
folled by a rinse in PBS. Samples were incubated 10 
minutes in buffered citrate 0.01 M, pH 6, twice and rinsed 
in PBS. Sections were then treated with BSA (5%) for 10 
minutes and finally incubated overnight with specific 
antibodies against CyD1 from NOVUS biologicals, used 
at 1:100 v/v and E2F1, Protein Tech, used at 1:50 v/v. 
Samples were then washed with PBS for 5 minutes and 
incubated with a labeled streptavidin biotin-peroxidase 
conjugate kit (Dako LSAB plus, cod. K0675, Dako 
Cytomation, Milan, Italy).  After washing in PBS for 10 
minutes, the sections were incubated with 3, 3-
diaminobenzidine-tetrahydrochloride (DAB, Sigma 
Aldrich) for 1–3 minutes. The specificity of the immune 
reaction was revealed by the absence of the primary 
antibodies. Lastly, the samples were counterstained with 
Mayer's Hematoxylin and observed under a Leica 
Microsystems. 
 
siRNA Selection  
The sequences of two siRNA duplexes were synthesized 
by Invitrogen. The sense sequence for CyD1 was 
GCUAUUGGAGGAUCAGUUUTT, the sense sequence 
for E2F1 was GUCACGCUAUGAGACCUCATT. We 
also used Invitrogen negative (AMBIV NEG CTL cat. 
4457287) and positive (AMBIV GAPDH SIRNA cat. 
4457288) controls in our experiment to evaluate the 
efficacy of silencing. 
 
Nanoliposomes encapsulating siRNAs preparation and 
characterization 
For nanoliposomes production, L-α-Phosphatidylcholine 
(PC) from egg yolk (CAS n. 8002-43-5), Cholesterol 
(CHO) (CAS n. 57-88-5), N-[1-(2,3-Dioleoyloxy)propyl]-
N,N,N-trimethylammonium chloride (DOTAP) (CAS n. 
132172-61-3) over 99% pure, Rhodamine B (CAS n. 81-
88-9), potassium phosphate monobasic (CAS n.7778-77-
0), sodium hydroxide (CAS n. 1310-73-2) and 
(hydroxymethyl)aminometane hydrochloride (Tris) were 
purchased from Sigma Aldrich (Milan, Italy) as dried 
powders and used without further purification. Silencer® 
Select siRNAs for CyD1 and E2F1 inhibition were 
purchased from Invitrogen; the sense sequences were the 
same as those above reported. All the other chemicals and 
reagents such as chloroform (CAS n. 67-66-3) and 
methanol (CAS n. 67-56-1) (Sigma Aldrich, Milan, Italy) 
used were of analytical grade. Nanoliposomes were 
prepared using thin film hydration method followed by 
duty cycle sonication as a size reduction method, 
developed by Barba and co-workers  [50,51]. For the 
production of nanoliposomes encapsulating siRNAs 
sequences, DOTAP, CHOL and PC at 1.5:1:3 (mol: mol) 
ratio were chosen to achieve a positively charged lipid 
bilayer. Briefly, lipids were dissolved in 2 mL of 
chloroform/methanol 2:1 (vol/vol). Evaporation in a rotary 
evaporator removed the solvent (Heidolph, Laborota 4002 
Control) and the produced lipid film was vacuum-dried 
for 3 hours at 50°C in a water bath. The dried lipid film 
was then hydrated at room temperature with 1 mL of Tris 
buffer solution (TBS - Tris(hydroxymethyl) aminometane 
hydrochloride 50 mM; sodium chloride 100 mM; pH 7.5), 
pre-warmed, containing 200 μl of 250 μM CyD1siRNA 
stock solution. The same procedure was done for 
E2F1siRNA encapsulation. 
By this way, a sample of Multilamellar Vesicles (MLVs) 
encapsulating siRNAs at 50 μM final concentration was 
obtained using a DOTAP/siRNA charge ratio of 5:1 (+/-). 
The production of nanoliposomes was obtained by 
maintaining at room temperature for 2 hours the 
preparation containing MLVs and then sonicated it at 45% 
amplitude (treated volume: 1 mL) applying a duty cycle 
consisting of 2 irradiation rounds of 10 seconds, each 
followed by 20 seconds of pause to prevent thermal 
vesicle disruption. The nanoliposomes were stored at 4°C 
for one night, protected from light, and was then sonicated 
at 45% amplitude for four more rounds to achieve suitable 
small unilamellar vesicles SUVs. In this work the VCX 
130 PB Ultrasonic Processors of Sonics & Materials Inc., 
USA instrument was used (its main features: maximum 
power 130 W, frequency 20 kHz; sonotrode tip length 137 
mm; sonotrode tip diameter 3 mm) [54]. 
To morphologically characterize the produced 
nanoliposomes and study their uptake in tissue, a sample 
of empty nanoliposomes labeled with Rhodamine B was 
also prepared. The empty nanoliposomes were similarly 
produced, but the pocedure followed by hydratation of the 
thin lipid film with phosphate buffer solution (PBS) 
containing only Rhodamine B. 
The lipids hydration solution contained potassium 
phosphate monobasic 0.2 M, sodium hydroxide 0.2 M and 
5 µl of 5 mg/ml Rhodamine B stock solution to a pH 7.4 
final solution. 
Morphological characterization of empty SUVs was 
performed using optical microscopy (Axioplan 2- Image 
Zeiss, Jena, Germany) for fluorescent imaging. A 63x oil 
immersion objective was used, taking advantage of the 
fluorochrome Rhodamine B to label and visualize the 
vesicles. 
The dimensional and zeta potential characterizations of 
SUVs containing siRNA sequences were done by Photon 
Correlation Spectroscopy (PCS). In particular, Dynamic 
Light Scattering analysis was performed by using the 
ZetasizerNano ZS (Malvern, UK) which incorporates 
noninvasive backscatter (NIBS) optics. The detection 
angle of 173 degrees was used. The resulting particle size 
distribution was plotted as the number of liposomes versus 
size. All the measurements were performed in triplicate. 
The results were expressed as average values. 
 
Nanoliposome-siRNAs complexes formation and 
stability  
A retardation assay was performed to study the effective 
formation of the nanoliposomes-siRNAs complexes and 
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their stability. A siRNAs silencer (1 μg) and 
nanoliposome-siRNA complexes, containing 1 μg of 
siRNAs were loaded into individual wells and subjected to 
electrophoresis on 1.5 % agarose gel (30 minutes at 80 V) 
in Tris/Borate/EDTA buffer (TBE) 0.5 M containing 45 
mM Tris-borate and 1 mM EDTA. After staining with 
ethidium bromide (0.5 μg/ml), gels were viewed with 
UltraBright LED Transilluminator (Maestrogen, USA) at 
470 nm. 
 
Nanoliposomes uptake in colon tissues 
A fluorescence assay was used to study the nanoliposomes 
uptake in tissue. For this purpose 20 μl of nanoliposomes 
labeled with Rhodamine B were incubated in colon biopsy 
and then cultured for 4 hours; then biopsy tissues were 
frozen at – 80 °C. Subsequently, four-micrometer frozen 
tissue sections of biopsy samples were obtained and 
individually incubated for 5 minutes with DAPI 
(Invitrogen, diluted 1:1000 with deionized water) and then 
mounted with Mounting media (using glycerol and PBS at 
5:1 v/v ratio). The liposome incorporation was studied by 
direct visualization of tissue section in fluorescence (Leica 
Microsystems). 
Ex vivo transfection in colon tissue with 
Invivofectamine® and nanoliposomes 
Colon tissues were cultured as before described. We 
transfected the biopsies with CyD1siRNA and E2F1 
siRNA at a final concentration of 5 nM using both the 
lipid mediated transfection carriers: Invivofectamine®® 
(commercial transfection reagent designed for systemic 
siRNA delivery) [55] and the produced nanoliposomes. 
As indicated by the manufacturer's protocol for Silencer® 
Select siRNAs, a final concentration of 2 to 10 nM can be 
used to reduce mRNA levels for more than 80 % 
(Guidelines for transfection of mammalian cultured cells, 
Life Technologies).The amount of the commercial 
transfection agent was adjusted taking into account that 
for in vivo transfection in mice 10 µl/g of 
Invivofectamine® (Invivofectamine® 2.0, Invitrogen, 
Life Technologies, Cat. no. 1377501) are used and 
considering the recommended ratio of 2:1:1 (v/v) between 
Invivofectamine®, siRNA and the complexation buffer, 
included in the Invivofectamine® kit. Thus, for 4 µl of 50 
µM siRNA stock solution, 4 µl of complexation buffer 
and 8 µl of Invivofectamine® were used. The siRNA was 
re-suspended with buffer complexation, and the solution 
was stirred vigorously before the addition of 
Invivofectamine®.  The solution was stirred again and 
incubated at 50 ° C for 30 minutes before use. The 
nanoliposomes loaded with siRNA were used maintaining 
the same final concentration of 5 nM, thus for siRNA 
transfection, 4 µl of the nanoliposomes stock solution was 
used. Samples were treated as described in tissue culture, 
then frozen at - 80 °C. 
Western blotting analysis 
The colon specimen were lysed in buffer [50 mmol/L 
Tris-HCl (pH 8.0), 150 mmol/L NaCl, 0.1% SDS, 1% 
NP40] supplemented with protease and phosphatase 
inhibitors (CalbioChem). The proteins present in 
supernatants were quantified with the Breadford method 
assay (Biorad). Samples of 40 µg total proteins from colon 
preparation were applied to 10% sodium dodecyl 
sulfate/polyacrylamide gel electrophoresis (SDS-PAGE) 
and then transferred onto nitrocellulose membrane 
(Biorad). Blotting membranes were incubated with 
blocking solution with 5% non-fat dried milk powder 
dissolved in Tris-Buffered Saline Tween-20 (TBST) 
buffer (pH 7.5, 10 mmol ⁄ L Tris–HCl, 150 mmol ⁄L NaCl, 
and 0.1% Tween20) for 1 h at room temperature, washed 
three times, and then incubated with rabbit monoclonal 
anti CyD1, (Novus Biologicals, cat. NB100-79920; 
1:5000 dilution) in TBST overnight at 4 °C.  After three 
washes with TBST buffer, we incubated the membranes 
for 1 hr with horseradish peroxidase–linked goat antirabbit 
secondary antibody (Immunoreagents Inc, 1:2000 
dilution). The same procedure was done using rabbit 
monoclonal anti phosphoE2F1 (Proteintech, 1:50 dilution) 
and COX-2 (Cell Signaling 12282, 1:1000) Internal 
control was carried out using β-Actin rabbit antibody 
(ABM, cat. Y080025; 1:1000 dilution). 
The membranes were then processed by using Chemidoc 
(Bio-rad, Laboratories S.r.l., Segrate, MI) and treated with 
enhanced chemiluminescence western blotting detection 
reagents (Clarity Western ECL Substrate, Biorad, cat. 
170-5060). The films were scanned, and the bands’ 
densitometry analysis was performed by using the ImageJ 
software for the relative level of the protein quantification. 
Cytotoxicity 
We observed that the morphology and viability of tissues 
were maintained (PZ pathologist), that could suggest a 
non-toxicity of nanoliposomes and Invivofectamine® in 
tissues.  
Statistics  







Cultures of human colon isolated from 6 different donors, 
two healthy controls (one male, one female) and four 
patients affected with Crohn’s disease (donor 1, white 
male, donor 2 white female; donor 3 white male, donor 4 
white female) were used. A good integrity of tissues was 
observed through the immunohistochemical analysis. Both 
cyclins expressions increased after LPS treatment. Figures 
1 show the CyD1 and E2F1 expression in a single patient 
as an example. The total number of Cyclin D1 and E2F1 
positive cells is increased in all the patients after EC-LPS 
treatment (26% and 23%, respectfully in comparison with 
basal, untreated condition). 
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Fig. 1.  
Microscope pictures of cultured colonic tissue after 
nuclear immunohistochemical analysis with the cyD1 
antibody.  (a) untreated tissue; (b)  EC-LPS treated tissue. 
Microscope pictures of cultured colonic tissue after 
immunohistochemical analysis with the E2F1 antibody. 
(c) untreated tissue; (d) EC-LPS treated tissue. (Results 
from one representative experiment) 
 
 Nanoliposomes characterization: morphology, size 
and zeta potential 
Spherical and defined liposomes were achieved through 
the production process before described. Figure 2 shows 
the nanoliposomal vesicles obtained before the sonication 
process and the nanoliposomal vesicles obtained after the 
duty cycle sonication process.  The diameter size, 
polydispersity index (PDI) and zeta potential of cationic 
nanoliposomes encapsulating siRNAs were analyzed, and 
the obtained values are summarized in Table 1, presented 
as the average of three determinations. The nanometric 
structures produced have the right dimension useful for 
the Enhance Permeability and Retention Effect (EPR 
effect) which occurs in both inflammation and cancer 
conditions. The homemade lipid nanoparticles can diffuse 
and penetrate through tumor vascular fenestrations of 50 – 
100 nm range size. Moreover, nanoliposomes are cationic 
as desired and as required to achieve an interaction with 
the negative siRNA molecule and also with the negatively 





Fig.2. Fluorescence microscope pictures of liposomal 
vesicles labelled with Rhodamine B (Obj 63X). On the 
left, microliposomal vesicles before the sonication 
process; on the right, nanoliposomes after the duty cycle 















Table 1. Small Unilamellar Vesicles (SUVs) loaded with 
siCyD1, and siE2F1 mean diameter size, polydispersity 
index and zeta potential. Results are expressed as the 
average of three determinations; SD is the standard 
deviation. 
Nanoliposome-siRNAs complexes formation and 
stability  
As visible in figure 3, the retardation assay has shown the 
formation of very stable siRNA-SUVs complexes. In lane 
2 and 4 any siRNA bands or bands smear are visible on an 
agarose gel, demonstrating the satisfactory encapsulation 
of siRNA molecules into nanoliposomes carriers projected 
including the positive charged DOTAP in the bilayer and 




M ± SD 
PDI M± SD Zeta Pot. 
(mV) M± SD 
siCyD1 SUVs 24.6 ± 5.0 0.42 ± 0.008 64.4 ± 1.85 
siE2F1 SUVs 47.2 ± 4.9 0.33 ± 0.02 75.5 ± 0.45 
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Fig. 3. Band shift assay of siRNA binding interaction. In 
lane 1 siRNA CyD1 (1 μg) is in its naked form and the 
relative band is well visible; in lane 2 siRNA CyD1 (1 μg) 
is encapsulated in nanoliposomes and the band is not 
visible demonstrating the formation of a stable complex. 
In lane 3 siRNA E2F1 (1 μg) is in its naked form and the 
relative band is visible while in lane 4 siRNA E2F1 (1 μg) 
is encapsulated in nanoliposomes and the band is not 
visible demonstrating again the formation of a very stable 
complex. In the assay patients samples run in parallel with 
two controls: a 100 bp Ladder molecular weight visible on 
the left and a 21 bp ds-DNA molecule (simulating "Homo 
sapiens siRNA probe Luciferase", 12833.4 g/mol) visible 
on the right. 
 
Nanoliposomes uptake in colonic tissues 
Fluorescence assay demonstrated the capacity of 
nanoliposomes to penetrate the colonic tissues. As shown 
in Figures 4, after four hours of incubation with 
Rhodamine labeled carriers, we observed the introduction 
of nanoliposomes in the biopsy tissue after the EC-LPS 
treatment. After four hours of incubation, nanoliposomes 





Fig. 4. Fluorescence microscope pictures of Small 
Unilamellar Vesicles in cultured colonic tissue (Obj. 
20X). Distribution of Rhodamine B-labeled SUVs in 
colonic mucosa sections in which nuclei are DAPI-labeled 
(time of incubation: 4 h) merge, Rhodamine and DAPI 
channels. 
 
Effects of ex vivo transfection in colon tissue with 
Invivofectamine®® and nanoliposomes 
To study the changes of the protein levels during the 
inflammatory processes, we analyzed the effect of EC-
LPS on CyD1, E2F1 and COX-2 expression in colon 
tissues. EC-LPS in the culture medium induced an 
increase of cyD 1, E2F1 and COX-2 expression in the 
mucosa. The silencing of cyD 1 and E2F1 showed a 
patient dependent response. Figure 5 shows an example of 
the response of E2F1 and cyD1 silencing both with 
invivofectamine and with nanoliposomes after EC-LPS 
treatment. COX-2 protein expression in the mucosa is 








Fig. 5. Evaluation of CyD1, E2F1 and COX-2 expression 
by Western Blot analysis of colon tissue samples from the 
patient 3 (PT3). Following the order of the analyzed 
samples: 1. Medium; 2. EC-LPS; 3. siRNA CyD1 
transfected with Invivofectamine®; 4. siRNA CyD1 
transfected in Nanoliposomes; 5. siRNA CyD1 in 
Invivofectamine® and EC-LPS; 6. siRNA CyD1 in 
Nanoliposomes and EC-LPS; 7. siRNA E2F1 transfected 
with Invivofectamine®; 8. siRNA E2F1 transfected in 
Nanoliposomes; 12. CTR – in Invivofectamine®; 9. 
siRNA E2F1 in Invivofectamine® and EC-LPS; 10. 
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DISCUSSION 
  
The present study investigated the potential utility of 
inhibiting E2F1 and CyD1 in modulating the 
inflammation process in human colonic tissue from 
patients affected with CD. These preliminary data 
demonstrated that gene silencing via RNA interference is 
possible and that tailored nanoliposomes may overcome 
the low penetration of siRNA across cell membranes 
which is a major obstacle for siRNA therapy. 
The present study has, however, several limitations. First, 
this is a pilot study and the number of patients included is 
not adequate to draw definitive conclusions. Moreover, 
the included patients express differences in gender, age, 
duration and characteristics of the disease that may have 
influenced the results.  
The silencing of CyD1 led to reduced protein expression 
in all patients. Silencing of E2F1 was differently effective 
in each patient. We demonstrated the inhibition of COX-2 
expression after cyD1 and E2F1 silencing, substantiating 
other studies indicating a correlation between COX-2 and 
cyclins in cancer [56-58].  
The present preliminary results make the basis for a 
potential gene therapy and “new smart nanovectors 
construction” able to treat IBD. Currently, commercial 
vectors can be used for all tissue indifferently. Thus, they 
lack tissue-specificity. If the aim is to reach specific cells 
and not others, there is the need for tissue-targeted 
systems. In the IBD therapy, both the siRNAs of choice 
and the nanocarriers should target specifically the 
inflamed colonic or ileal mucosa, reducing the systemic 
effect. Recently, our group identified siE2F1 
nanoliposomes formulation (called siE2F1-SUV) with a 
better efficacy of uptake and silencing of E2F1 in cultured 
human biopsy of colonic mucosa and colon carcinoma 
cells [59]. However, in our opinion, the individual 
response is the key factor. In fact, the present data show 
that we obtained a patient-dependent response to the same 
silencing strategy.  Ideally, in the future, researchers could 
achieve optimized nanoliposomes and siRNA specific for 
the single patient, to test for efficacy first on the patient's 




This study shows the preliminary results of the potential 
use of purposely formulated and produced siRNA vectors 
to deliver CyD1 and E2F1 siRNAs in control 
inflammation and cancer progression in IBD using the  
colon tissue culture  in vitro model that represents a good 
example of translational medicine described as a tool to 
bring scientific knowledge "from bench to bedside" and 
then develop new therapies or medical procedures. Further 
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